LifeStance Health Group, Inc.
LFST- Exchange
- Nasdaq
- Industry
- Services-Health Services
- SEC CIK
- 0001845257
In the last 90 days, LifeStance Health Group, Inc. insiders filed 0 open-market purchases and 4 sales; 291 institutions reported holding it in 13F filings for Q2 2026, worth $4.02B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 11:00 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 27, 2025 | Feb 2, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Revenue | $1.42B | $1.25B | $1.06B | $859.5M | $667.5M |
| Operating expenses | $1.40B | $1.28B | $1.24B | $1.07B | $953.9M |
| Selling, general and administrative | $382.2M | $363.1M | $410.8M | $378.0M | $433.7M |
| Operating income | $24.1M | -$31.6M | -$189.1M | -$210.2M | -$286.4M |
| Interest expense | $11.7M | $26.5M | $21.2M | $19.9M | $38.9M |
| Income tax | $2.70M | -$170.0K | -$20.3M | -$17.2M | -$25.9M |
| Net income | $9.66M | -$57.4M | -$186.3M | -$215.6M | -$307.2M |
| Weighted shares, basic | 386.0M | 379.1M | 367.5K | 355.3K | – |
| Weighted shares, diluted | 391.1M | 379.1M | 367.5K | – | – |
| Margins and growth | |||||
| Operating margin | 1.7% | -2.5% | -17.9% | -24.5% | -42.9% |
| Net margin | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% |
| Revenue growth, year over year | +13.9% | +18.5% | +22.8% | +28.8% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 27, 2025 | Feb 2, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Cash and equivalents | $248.6M | $154.6M | $78.8M | $108.6M | $148.0M |
| Accounts receivable | $95.7M | $131.8M | $125.4M | $100.9M | $76.1M |
| Total current assets | $416.2M | $312.5M | $225.7M | $233.2M | $266.5M |
| Property, plant and equipment | $161.6M | $166.0M | $188.2M | $194.2M | $152.2M |
| Goodwill | $1.29B | $1.29B | $1.29B | $1.27B | $1.20B |
| Intangible assets | $177.7M | $190.8M | $221.1M | $263.3M | $300.4M |
| Total assets | $2.20B | $2.12B | $2.11B | $2.17B | $1.93B |
| Accounts payable | $6.12M | $7.24M | $7.05M | $12.3M | $14.2M |
| Short-term debt | $14.5M | $7.25M | $2.92M | $2.35M | $1.32M |
| Total current liabilities | $252.0M | $228.9M | $202.9M | $176.0M | $116.8M |
| Long-term debt | $265.9M | $279.8M | $280.3M | $225.1M | $157.4M |
| Total liabilities | $682.9M | $672.0M | $681.0M | $655.1M | $382.1M |
| Shareholders' equity | $1.52B | $1.45B | $1.43B | $1.52B | $1.55B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 27, 2025 | Feb 2, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Operating cash flow | $146.2M | $107.3M | -$16.9M | $52.8M | $9.42M |
| Capital expenditures | $36.1M | $21.6M | $40.5M | $79.3M | $94.5M |
| Free cash flow | $110.0M | $85.7M | -$57.4M | -$26.5M | -$85.1M |
| Depreciation and amortization | $41.6M | $40.7M | $37.4M | $28.9M | $15.1M |
| Stock-based compensation | $74.7M | $76.2M | $99.4M | $187.4M | $259.4M |
| Investing cash flow | -$36.1M | -$21.6M | -$60.3M | -$139.5M | -$194.1M |
| Financing cash flow | -$16.0M | -$9.95M | $47.4M | $47.3M | $313.9M |
| Net change in cash | $94.1M | $75.7M | -$29.8M | -$39.4M | $129.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5.2% | 6.1% | 9.4% | 21.8% | 38.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 380.2M | −2.3% | SEC |
| Jul 29, 2026 | 382.1M | −1.8% | SEC |
| Apr 29, 2026 | 387.8M | −0.3% | SEC |
| Feb 17, 2026 | 389.8M | +1.4% | SEC |
| Oct 29, 2025 | 389.0M | +1.7% | SEC |
| Jul 30, 2025 | 388.9M | +1.7% | SEC |
| Apr 30, 2025 | 388.9M | +1.7% | SEC |
| Feb 19, 2025 | 384.6M | +1.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.